Enzon Pharmaceuticals Inc. (OTCMKTS:ENZN - Get Free Report) shares crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $5.74 and traded as high as $7.20. Enzon Pharmaceuticals shares last traded at $6.98, with a volume of 1,822 shares.
Enzon Pharmaceuticals Stock Performance
The firm's fifty day moving average price is $6.20 and its 200 day moving average price is $5.74. The firm has a market cap of $518.02 million, a P/E ratio of -99.70 and a beta of 0.20.
Enzon Pharmaceuticals (OTCMKTS:ENZN - Get Free Report) last announced its earnings results on Monday, March 2nd. The biotechnology company reported ($2.00) EPS for the quarter.
About Enzon Pharmaceuticals
(
Get Free Report)
Enzon Pharmaceuticals, Inc, headquartered in Piscataway, New Jersey, is a specialized biopharmaceutical company best known for pioneering polyethylene glycol (PEG) technology to enhance the pharmacokinetic properties of therapeutic proteins. Founded in 1981, Enzon has leveraged its PEGylation platform to develop an array of oncology and hematology products with improved half-life and reduced immunogenicity.
The company's flagship product, Oncaspar (pegaspargase), was originally approved for the treatment of acute lymphoblastic leukemia in pediatric and adult patients, highlighting Enzon's commitment to oncology.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Enzon Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Enzon Pharmaceuticals wasn't on the list.
While Enzon Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
